Efficacy, safety and cost of emicizumab prophylaxis in haemophilia A patients with inhibitors: A nationwide observational study in Taiwan.
Ming-Ching ShenSheng-Chieh ChouShyh-Shin ChiouPei-Chin LinYeu-Chin ChenHsuan-Yu LinYang-Cheng LeeCih-En HuangTe-Fu WengTing-Huan HuangChih-Yuan ChungJiann-Shiuh ChenShu-Huey ChenShin-Nan ChengChih-Cheng HsiaoYen-Min HuangShih-Hsiang ChenYuan-Bin YuShih-Chiang LinChing-Yeh LinChing-Tien PengJiaan-Der Wangnull nullPublished in: Haemophilia : the official journal of the World Federation of Hemophilia (2023)
HA patients with FVIII inhibitors treated with emicizumab prophylaxis resulted in a significant reduction in treated bleeds and associated costs. No new safety events were observed.
Keyphrases